Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.

Urushiyama H, Jo T, Yasunaga H, Michihata N, Matsui H, Hasegawa W, Takeshima H, Sakamoto Y, Hiraishi Y, Mitani A, Fushimi K, Nagase T, Yamauchi Y.

Cancer Med. 2018 Oct;7(10):4863-4869. doi: 10.1002/cam4.1725. Epub 2018 Aug 27.

2.

Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.

Kenmotsu H, Ohde Y, Wakuda K, Nakashima K, Omori S, Ono A, Naito T, Murakami H, Kojima H, Takahashi S, Isaka M, Endo M, Takahashi T.

Cancer Chemother Pharmacol. 2017 Sep;80(3):609-614. doi: 10.1007/s00280-017-3400-z. Epub 2017 Jul 31.

PMID:
28761967
3.

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).

Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G; Gruppo Oncologico Italia Meridionale.

Lung Cancer. 2008 Sep;61(3):369-77. doi: 10.1016/j.lungcan.2008.01.010. Epub 2008 Mar 4.

PMID:
18308419
4.

Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.

Shukuya T, Takahashi T, Tamiya A, Ono A, Igawa S, Tsuya A, Nakamura Y, Murakami H, Naito T, Kaira K, Endo M, Yamamoto N.

Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147. Epub 2009 Jan 12.

PMID:
19139038
5.

Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.

Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N.

Respir Investig. 2012 Dec;50(4):157-61. doi: 10.1016/j.resinv.2012.09.002. Epub 2012 Oct 27.

PMID:
23199980
6.

First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.

Gebbia V, Lorusso V, Galetta D, Caruso M M, Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferraù F, Cinieri S, Mancuso G, Mancarella S, Colucci G.

Lung Cancer. 2010 Aug;69(2):218-24. doi: 10.1016/j.lungcan.2009.10.008. Epub 2009 Nov 11.

PMID:
19910076
7.

Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.

Shukuya T, Takahashi T, Harada H, Akamatsu H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N.

Anticancer Res. 2012 Feb;32(2):675-80.

PMID:
22287762
8.

Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.

Logan DM, Lochrin CA, Darling G, Eady A, Newman TE, Evans WK.

Cancer Prev Control. 1997 Dec;1(5):366-78.

PMID:
9765759
9.

Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.

Martoni AA, Melotti B, Sperandi F, Giaquinta S, Piana E, Pavesi L, Da Prada G, Lelli G.

Lung Cancer. 2008 Jun;60(3):387-92. Epub 2007 Dec 26.

PMID:
18160123
10.

Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.

Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco A, Comella G.

J Clin Oncol. 1999 May;17(5):1526-34.

PMID:
10334540
11.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P.

Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

PMID:
16945766
12.

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.

Bennouna J, Senellart H, Hiret S, Vaissiere N, Douillard JY.

Lung Cancer. 2011 Oct;74(1):30-4. doi: 10.1016/j.lungcan.2011.02.004. Epub 2011 Mar 3.

PMID:
21371774
13.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.

Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.

PMID:
24521819
14.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
15.

Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).

Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P; Southern Italy Cooperative Oncology Group.

Ann Oncol. 2007 Feb;18(2):324-30. Epub 2006 Oct 27.

PMID:
17071935
16.

[The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].

Hirai Y, Shimizu Y, Oura S, Yoshimasu T, Ota F, Nakamura R, Naito K, Nishiguchi H, Hashimoto S, Okamura Y.

Gan To Kagaku Ryoho. 2012 Mar;39(3):381-4. Japanese.

PMID:
22421763
17.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).

Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators.

J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.

18.

Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.

Naito Y, Kubota K, Nihei K, Fujii T, Yoh K, Niho S, Goto K, Ohmatsu H, Saijo N, Nishiwaki Y.

J Thorac Oncol. 2008 Jun;3(6):617-22. doi: 10.1097/JTO.0b013e3181753b38.

19.

Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.

Ou W, Sun HB, Ye X, Zhang BB, Yang H, Fang Q, Li P, Wang SY.

J Thorac Oncol. 2010 Jul;5(7):1033-41. doi: 10.1097/JTO.0b013e3181d95db4.

20.

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

Sonobe M, Okubo K, Teramukai S, Yanagihara K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, Omasa M, Sakai H, Miyahara R, Bando T, Date H.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1199-206. doi: 10.1007/s00280-014-2595-5. Epub 2014 Sep 25.

PMID:
25253046

Supplemental Content

Support Center